Shares

15 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 15, 2024

SELL
$0.0 - $329.83 $0 - $172 Million
-522,000 Closed
0 $0
Q4 2023

May 15, 2024

BUY
$161.01 - $317.85 $84 Million - $166 Million
522,000 New
522,000 $165 Million
Q3 2023

Nov 14, 2023

BUY
$164.66 - $218.08 $362,252 - $479,776
2,200 New
2,200 $371,000
Q4 2022

Feb 14, 2023

SELL
$191.53 - $236.82 $14.9 Million - $18.4 Million
-77,800 Reduced 97.25%
2,200 $432,000
Q3 2022

Nov 14, 2022

SELL
$123.79 - $277.42 $2.48 Million - $5.55 Million
-20,000 Reduced 20.0%
80,000 $18 Million
Q2 2022

Aug 15, 2022

SELL
$93.97 - $143.33 $23.5 Million - $35.8 Million
-250,000 Reduced 71.43%
100,000 $12.7 Million
Q1 2022

May 16, 2022

SELL
$98.9 - $132.37 $19.8 Million - $26.5 Million
-200,000 Reduced 36.36%
350,000 $44.4 Million
Q4 2021

Feb 14, 2022

SELL
$110.64 - $159.4 $16.6 Million - $23.9 Million
-150,000 Reduced 21.43%
550,000 $72.1 Million
Q3 2021

Nov 15, 2021

BUY
$101.2 - $125.87 $7.08 Million - $8.81 Million
70,000 Added 11.11%
700,000 $85.6 Million
Q2 2021

Aug 13, 2021

SELL
$107.45 - $135.95 $4.84 Million - $6.12 Million
-45,000 Reduced 6.67%
630,000 $71.8 Million
Q1 2021

May 17, 2021

SELL
$95.46 - $133.08 $2.39 Million - $3.33 Million
-25,000 Reduced 3.57%
675,000 $81.2 Million
Q3 2020

Nov 16, 2020

BUY
$71.31 - $109.74 $8.91 Million - $13.7 Million
125,000 Added 21.74%
700,000 $54.1 Million
Q2 2020

Aug 14, 2020

BUY
$62.14 - $117.21 $494,199 - $932,171
7,953 Added 1.4%
575,000 $64.1 Million
Q1 2020

May 15, 2020

SELL
$60.41 - $115.92 $1.99 Million - $3.82 Million
-32,953 Reduced 5.49%
567,047 $40.8 Million
Q4 2019

Feb 13, 2020

BUY
$11.44 - $123.99 $6.86 Million - $74.4 Million
600,000 New
600,000 $45.2 Million

Others Institutions Holding KRTX

About Karuna Therapeutics, Inc.


  • Ticker KRTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 33,965,000
  • Description
  • Karuna Therapeutics, Inc., a clinical-stage biopharmaceutical company, creates and delivers transformative medicines for people living with psychiatric and neurological conditions. Its lead product candidate is KarXT, an oral modulator of muscarinic receptors that is in Phase III clinical trial for the treatment of acute psychosis in patients wi...
More about KRTX
Track This Portfolio

Track Farallon Capital Management LLC Portfolio

Follow Farallon Capital Management LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Farallon Capital Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Farallon Capital Management LLC with notifications on news.